Access the full text.
Sign up today, get DeepDyve free for 14 days.
Eran Weinmann, Edwin Salzman (1994)
Deep-vein thrombosis.The New England journal of medicine, 331 24
S. Rule, S. O’Brien, L. Crossman (2002)
Managing cutaneous reactions to imatinib therapy.Blood, 100 9
G. Oster, R. Tuden, G. Colditz (1987)
A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery.JAMA, 257 2
R. Hull, G. Pineo, G. Raskob (1998)
The Economic Impact of Treating Deep Vein Thrombosis with Low-Molecular-Weight Heparin: Outcome of Therapy and Health Economy AspectsPathophysiology of Haemostasis and Thrombosis, 28
K. Bauer, D. Hawkins, P. Peters, M. Petitou, J. Herbert, C. Boeckel, D. Meuleman (2006)
Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors.Cardiovascular drug reviews, 20 1
Marc Rodger, Christopher Bredeson, Philip Wells, Julie Beck, Brenda Kearns, Lothar Huebsch (1998)
Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 159 8
Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients
A. Gordois, J. Posnett, L. Borris, P. Bossuyt, B. Jônsson, Elena Levy, G. Pouvourville (2003)
The cost‐effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgeryJournal of Thrombosis and Haemostasis, 1
K. Bauer, B. Eriksson, M. Lassen, A. Turpie (2002)
Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolismCurrent Opinion in Pulmonary Medicine, 8
Michael Kovacs, David Anderson, B. Morrow, L. Gray, D. Touchie, P. Wells (2000)
Outpatient Treatment of Pulmonary Embolism with DalteparinThrombosis and Haemostasis, 83
M.R. Lassen, K.A. Bauer, B.I. Eriksson (2002)
Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparisonLancet, 359
A. Turpie, K. Bauer, B. Eriksson, M. Lassen (2002)
Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trialThe Lancet, 359
K. Bauer, B. Eriksson, M. Lassen, A. Turpie (2001)
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.The New England journal of medicine, 345 18
E. Friesen, D. Lier, J. Bachynsky, P. Jacobs (2002)
An Economic Comparison of Enoxaparin and Warfarin in the Prevention of Deep Vein Thrombosis after Hip and Knee ReplacementThe Canadian Journal of Hospital Pharmacy, 55
S.D. Sullivan, B.L. Davidson, S.R. Kahn (2002)
Cost effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing major orthopedic surgery [abstract]Blood, 100
S.D. Sullivan, S.R. Kahn, B.L. Davidson (2003)
Measuring outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgeryPharmacoeconomics, 21
B. Eriksson, K. Bauer, M. Lassen, A. Turpie (2001)
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.The New England journal of medicine, 345 18
F. Stadil (1970)
Prevention of venous thrombosis.Lancet, 2 7662
A. Turpie, K. Bauer, B. Eriksson, M. Lassen (2002)
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.Archives of internal medicine, 162 16
G. Pineo (2001)
New Developments in the Prevention and Treatment of Venous ThromboembolismPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 21
Am J Cardiovasc Drugs 2004; 4 (5): 325-333 ORIGINAL RESEARCH ARTICLE 1175-3277/04/0005-0325/$31.00/0 © 2004 Adis Data Information BV. All rights reserved. Pharmacoeconomic Analysis of Fondaparinux Versus Enoxaparin for the Prevention of Thromboembolic Events in Orthopedic Surgery Patients 1 2 3 4 5 6 George Dranitsaris, Susan R. Kahn, Carmine Stumpo, Thomas W. Paton, Josee Martineau, Reginald Smith, Jeffrey S. Ginsberg on behalf of The Fondaparinux Canadian Health Economic Study Investigators 1 Augmentium Pharma Consulting, Toronto, Ontario, Canada 2 Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada 3 Toronto East General Hospital, Toronto, Ontario, Canada 4 Sunnybrook and Women’s College Health Sciences Centre, Toronto, Ontario, Canada 5 Cite de la Sant ´ e, Laval, Quebec, Canada ´ 6 Royal Jubilee Hospital, Victoria, British Columbia, Canada 7 McMaster University, Hamilton, Ontario, Canada Abstract Introduction: Fondaparinux is a novel synthetic antithrombotic that has been evaluated for the prevention of venous thromboembolism (VTE). In four large trials in patients who underwent major hip or knee surgery, fondaparinux was found to have a good safety profile and be more effective than enoxaparin. To generate Canadian pharmacoeconomic data for fondaparinux, an internationally developed cohort deterministic model was used to estimate the costs and
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 17, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.